Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with ageShow others and affiliations
2023 (English)In: Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, E-ISSN 1091-6490, Vol. 120, no 12, article id e2220320120Article in journal (Refereed) Published
Abstract [en]
Pre-existing SARS-CoV-2-reactive T cells have been identified in SARS-CoV-2-unexposed individuals, potentially modulating COVID-19 and vaccination outcomes. Here, we provide evidence that functional cross-reactive memory CD4+ T cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is established in early childhood, mirroring early seroconversion with seasonal human coronavirus OC43. Humoral and cellular immune responses against OC43 and SARS-CoV-2 were assessed in SARS-CoV-2-unexposed children (paired samples at age two and six) and adults (age 26 to 83). Pre-existing SARS-CoV-2-reactive CD4+ T cell responses targeting spike, nucleocapsid, and membrane were closely linked to the frequency of OC43-specific memory CD4+ T cells in childhood. The functional quality of the cross-reactive memory CD4+ T cell responses targeting SARS-CoV-2 spike, but not nucleocapsid, paralleled OC43-specific T cell responses. OC43-specific antibodies were prevalent already at age two. However, they did not increase further with age, contrasting with the antibody magnitudes against HKU1 (β-coronavirus), 229E and NL63 (α-coronaviruses), rhinovirus, Epstein–Barr virus (EBV), and influenza virus, which increased after age two. The quality of the memory CD4+ T cell responses peaked at age six and subsequently declined with age, with diminished expression of interferon (IFN)-γ, interleukin (IL)-2, tumor necrosis factor (TNF), and CD38 in late adulthood. Age-dependent qualitative differences in the pre-existing SARS-CoV-2-reactive T cell responses may reflect the ability of the host to control coronavirus infections and respond to vaccination. Copyright © 2023 the Author(s).
Place, publisher, year, edition, pages
National Academy of Sciences , 2023. Vol. 120, no 12, article id e2220320120
Keywords [en]
ADP ribosyl cyclase/cyclic ADP ribose hydrolase 1; gamma interferon; interleukin 2; tumor necrosis factor; adult; adulthood; aged; Article; CD4+ T lymphocyte; cellular immunity; child; childhood; comorbidity; controlled study; coronavirus disease 2019; cross reaction; female; human; humoral immunity; major clinical study; male; memory T lymphocyte; nonhuman; protein expression; seroconversion; Severe acute respiratory syndrome coronavirus 2; virus nucleocapsid; virus spike
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-200780DOI: 10.1073/pnas.2220320120ISI: 001174137600001PubMedID: 36917669Scopus ID: 2-s2.0-85150431616OAI: oai:DiVA.org:liu-200780DiVA, id: diva2:1835991
Note
Funding Agencies|European Molecular Biology Organization (EMBO) [(ALTF 1062-2020)]; Svenska Sallskapet for Medicinsk Forskning (SSMF) Postdoctoral Fellowship; Swedish Research Council [2020-02033]; South-Eastern Norway Regional Health Authority; Stockholm County Council [FoUI-953862]; Swedish Cancer Society [20 0176 Pj]; Centrum for Innovative Medicine (CIMED); Knut and Alice Wallenberg Foundation [2021.0136]; European Research Council [101057129, 101041484]; Karolinska Institutet [2019-00931, 2020-01599]; Swedish Childhood Cancer Fund [PR2020-0072]; Ake Wibergs Stiftelse [M20-0190]; Jonas Soderquist Stiftelse; Sven and Ebba-Christina Hagbergs stiftelse.A.C.K; CIMED project grant [20190495]; Swiss National Science Foundation [31CA30 196046]
2024-02-072024-02-072024-12-02